The Relationship of IL 17a, Vit-D Levels and some Biochemical Markers with Psoriasis and the Effect of Oral Vitamin D Supplementation on Clinical Amelioration of the Disease

Year 2022, Volume: 8 Issue: 3, 59 - 64, 30.11.2022

Ahmed Najim Abbood Al-malıkı , Şevki Adem , Hussien Ali Nayyef

https://doi.org/10.22399/ijcesen.1111117

Abstract

The aim of the study was to measure vitamin D levels before and after giving specific doses of it. Patients with psoriasis have an imbalance in vitamin D levels, as vitamin D levels have been correlated with the level of disease progression. Psoriasis incidence rates after administration of vitamin D at a dose of 1 month every day 2000 IU, then the second and third month every week 10,000 IU for period a 3-month indicate that the size of the affected area did not expand or stopped expanding. Also in our study, interleukin-17 levels and lipid profile showed some changes, indicating that high levels of vitamin D may reduce inflammation or inflammatory diseases by contributing to immune system activation. There were notable changes in average lipids and the effect was likely caused by changes in vitamin D levels, which play an important role in lipid metabolism. There was also a decrease in calcium levels.

Keywords

Psoriasis, Total cholesterol, Vit-D, Total cholesterol Vit-D

References

• [1] Neagu, M., Constantin, C., Caruntu, C., Dumitru, C., Surcel, M. and Zurac, S. 2019. Inflammation: A key process in skin tumorigenesis. Oncology Letters, 17(5): 4068-4084.
• [2] Lowes, M. A., Bowcock, A. M. and Krueger, J. G. 2007. Pathogenesis and therapy of psoriasis. Nature, 445(7130): 866-873.
• [3] Schön, M. P. 2008. Animal models of psoriasis: a critical appraisal. Experimental Dermatology, 17(8): 703-712.
• [4] Pezzolo, E. and Naldi, L. 2019. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology, 15(1): 41-48.
• [5] Gu, Y., Hu, X., Liu, C., Qv, X. and Xu, C. 2008. Interleukin (IL)‐17 promotes macrophages to produce IL‐8, IL‐6 and tumour necrosis factor‐α in aplastic anaemia. British Journal of Haematology, 142(1): 109-114.
• [6] Blauvelt, A. 2007. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Review of Dermatology, 2(1): 69-78.
• [7] Han, Y., Ye, A., Bi, L., Wu, J., Yu, K. and Zhang, S. 2014. Th17 cells and interleukin‐17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Science, 105(8): 933-942.
• [8] Gaffen, S. L. 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Current Rheumatology Reports, 11(5): 365-370.
• [9] Stanescu, A. M. A., Simionescu, A. A. and Diaconu, C. C. 2021. Oral vitamin D therapy in patients with psoriasis. Nutrients, 13(1): 163.
• [10] Barrea, L., Savanelli, M. C., Di Somma, C., Napolitano, M., Megna, M., Colao, A. and Savastano, S. 2017. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Reviews in Endocrine and Metabolic Disorders, 18(2): 195-205.
• [11] Filoni, A., Vestita, M., Congedo, M., Giudice, G., Tafuri, S. and Bonamonte, D. 2018. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: An observational case-control study. Medicine, 97: (25).
• [12] Kirkham, B. W., Kavanaugh, A. and Reich, K. 2014. Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology, 141(2): 133-142.
• [13] Girolomoni, G., Mrowietz, U. and Paul, C. 2012. Psoriasis: rationale for targeting interleukin‐17. British Journal of Dermatology, 167(4): 717-724.
• [14] Pietrzak, A., Michalak-Stoma, A., Chodorowska, G. and Szepietowski, J. C. 2010. Lipid disturbances in psoriasis: an update. Mediators of inflammation, 2010.